Cargando…

Persistence of protective anti-poliovirus antibody levels in 4-year-old children previously primed with Picovax®, a trivalent, aluminium-adjuvanted reduced dose inactivated polio vaccine

BACKGROUND: To meet the demand for effective and affordable inactivated polio vaccines (IPVs), a reduced dose, aluminium hydroxide (Al(OH)(3))-adjuvanted IPV vaccine was developed (IPV-Al, Picovax®) and evaluated in clinical trials. The present trial is an extension of two previous trials (a primary...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sáez-Llorens, Xavier, Chan, Milagros, DeAntonio, Rodrigo, Petersen, Torben, Olesen, Charlotte, Jensen, Jens Søndergaard, Sørensen, Charlotte, Ekstrand, Lena Messerschmidt, Czort, Michaela Katrine, Kristensen, Hans-Henrik, Thulstrup, Niels, Christoffersen, Dorte Birk
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Science 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9488130/ https://www.ncbi.nlm.nih.gov/pubmed/36064670 http://dx.doi.org/10.1016/j.vaccine.2022.06.084

Ejemplares similares

Reduced mucosal immunity to poliovirus after cessation of trivalent oral polio vaccine
por: Zhao, Ting, et al.
Publicado: (2021)

Environmental Surveillance of Polioviruses in Armenia, Colombia before Trivalent Oral Polio Vaccine Cessation
por: González, María Mercedes, et al.
Publicado: (2019)

Introduction of Inactivated Poliovirus Vaccine and Trivalent Oral Polio Vaccine/Bivalent Oral Polio Vaccine Switch in the African Region
por: Tevi-Benissan, Carol, et al.
Publicado: (2017)

Intestinal Immunity to Poliovirus Following Sequential Trivalent Inactivated Polio Vaccine/Bivalent Oral Polio Vaccine and Trivalent Inactivated Polio Vaccine–only Immunization Schedules: Analysis of an Open-label, Randomized, Controlled Trial in Chilean Infants
por: Brickley, Elizabeth B, et al.
Publicado: (2018)

Vaccine-related poliovirus shedding in trivalent polio vaccine and human immunodeficiency virus status: analysis from under five children
por: Hassan, Joanne, et al.
Publicado: (2017)

Resource Needs for the Trivalent Oral Polio to Bivalent Oral Polio Vaccine Switch in Indonesia
por: Holmes, Marionette, et al.
Publicado: (2017)

Community transmission of type 2 poliovirus after cessation of trivalent oral polio vaccine in Bangladesh: an open-label cluster-randomised trial and modelling study
por: Taniuchi, Mami, et al.
Publicado: (2017)

Circulating Vaccine Derived Poliovirus and the polio eradication endgame
por: Davis, Robert, et al.
Publicado: (2012)

Reflections on Modeling Poliovirus Transmission and the Polio Eradication Endgame
por: Thompson, Kimberly M., et al.
Publicado: (2020)

Introduction of Inactivated Poliovirus Vaccine and Switch from Trivalent to Bivalent Oral Poliovirus Vaccine — Worldwide, 2013–2016
Publicado: (2015)

Preventing Vaccine-Derived Poliovirus Emergence during the Polio Endgame
por: Pons-Salort, Margarita, et al.
Publicado: (2016)

Type 2 poliovirus detection after global withdrawal of trivalent oral vaccine
por: Blake, Isobel M., et al.
Publicado: (2018)

Polio endgame risks and the possibility of restarting the use of oral poliovirus vaccine
por: Duintjer Tebbens, Radboud J., et al.
Publicado: (2018)

In-Vitro Inactivation of Sabin-Polioviruses for Development of Safe and Effective Polio Vaccine
por: Abd-Elghaffar, Asmaa A., et al.
Publicado: (2020)

Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of inadvertent trivalent oral poliovirus vaccine use
por: Duintjer Tebbens, Radboud J., et al.
Publicado: (2016)

The Switch From Trivalent to Bivalent Oral Poliovirus Vaccine in the South-East Asia Region
por: Bahl, Sunil, et al.
Publicado: (2017)

Impact of inactivated poliovirus vaccine on mucosal immunity: implications for the polio eradication endgame
por: Parker, Edward PK, et al.
Publicado: (2015)

Assessing the Risks for Poliovirus Outbreaks in Polio-Free Countries — Africa, 2012–2013
Publicado: (2013)

Patients with Primary Immunodeficiencies Are a Reservoir of Poliovirus and a Risk to Polio Eradication
por: Aghamohammadi, Asghar, et al.
Publicado: (2017)

Circulating vaccine-derived poliovirus: a menace to the end game of polio eradication
por: Ming, Long Chiau, et al.
Publicado: (2020)

The resurgence of wild poliovirus in Pakistan and Afghanistan: A new setback for polio eradication
por: Rana, Muhammad Suleman, et al.
Publicado: (2022)

Immunogenicity of New Primary Immunization Schedules With Inactivated Poliovirus Vaccine and Bivalent Oral Polio Vaccine for the Polio Endgame: A Review
por: Bandyopadhyay, Ananda S, et al.
Publicado: (2018)

Poliovirus excretion following vaccination with live poliovirus vaccine in patients with primary immunodeficiency disorders: clinicians’ perspectives in the endgame plan for polio eradication
por: Galal, Nermeen M., et al.
Publicado: (2018)

Experience With Inactivated Polio Vaccine Introduction and the “Switch” From Trivalent to Bivalent Oral Polio Vaccine in the World Health Organization’s Western Pacific Region
por: Gurung, Santosh, et al.
Publicado: (2017)

Challenges associated with the recent outbreaks of wild-type Poliovirus in previously polio-free countries
por: Arya, Subhash C., et al.
Publicado: (2013)

Interim CDC Guidance for Polio Vaccination for Travel to and from Countries Affected by Wild Poliovirus
por: Wallace, Gregory S., et al.
Publicado: (2014)

Review of poliovirus modeling performed from 2000 to 2019 to support global polio eradication
por: Thompson, Kimberly M., et al.
Publicado: (2020)

Twenty-Eight Years of Poliovirus Replication in an Immunodeficient Individual: Impact on the Global Polio Eradication Initiative
por: Dunn, Glynis, et al.
Publicado: (2015)

Environmental surveillance of poliovirus and non-polio enterovirus in urban sewage in Dakar, Senegal (2007-2013)
por: Ndiaye, Abdou Kader, et al.
Publicado: (2014)

Eliminating all circulating vaccine-derived poliovirus: a prerequisite to declaring global polio eradication
por: Durrheim, David N
Publicado: (2022)

Polio eradication vaccine investment: how do we ensure polio vaccines are available to keep the world polio-free after transmission of wild poliovirus (wPV) has been interrupted?
por: Batson, Amie, et al.
Publicado: (2021)

Financial Support to Eligible Countries for the Switch From Trivalent to Bivalent Oral Polio Vaccine—Lessons Learned
por: Shendale, Stephanie, et al.
Publicado: (2017)

Immunity and field efficacy of type 2-containing polio vaccines after cessation of trivalent oral polio vaccine: A population-based serological study in Pakistan
por: Voorman, Arie, et al.
Publicado: (2020)

La sorveglianza ambientale per poliovirus e non-polio enterovirus a Parma nell’ambito del “Global Polio Eradication Program” (GPEI)
por: Zoni, Roberta, et al.
Publicado: (2019)

Regulatory Aspects of Sabin Type 2 Withdrawal From Trivalent Oral Poliovirus Vaccine: Process and Lessons Learned
por: Decina, Daniela, et al.
Publicado: (2017)

Poliomyelitis seroprevalence in high risk populations of India before the trivalent-bivalent oral poliovirus vaccine switch in 2016
por: Ahmad, Mohammad, et al.
Publicado: (2021)

Environmental Surveillance of Polioviruses in Rio de Janeiro, Brazil, in Support to the Activities of Global Polio Eradication Initiative
por: de Oliveira Pereira, Joseane Simone, et al.
Publicado: (2015)

Intradermal Administration of Fractional Doses of Inactivated Poliovirus Vaccine: A Dose-Sparing Option for Polio Immunization
por: Okayasu, Hiromasa, et al.
Publicado: (2017)

Contribution of Contact Sampling in Increasing Sensitivity of Poliovirus Detection During A Polio Outbreak—Somalia, 2013
por: Moturi, Edna, et al.
Publicado: (2016)

Effect of HIV-exposure and timing of anti-retroviral treatment on immunogenicity of trivalent live-attenuated polio vaccine in infants
por: Moonsamy, Shelina, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_e6gsafifgmtbc8hjbevvig7le3